Canada markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2700+0.0400 (+3.25%)
At close: 4:00PM EDT
1.2700 0.00 (0.00%)
After hours: 05:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.2300
Open1.2400
Bid1.2100 x 800
Ask1.2900 x 2900
Day's Range1.1800 - 1.2700
52 Week Range0.9600 - 5.0000
Volume130,847
Avg. Volume505,575
Market Cap41.198M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.3200
Earnings DateNov. 08, 2021 - Nov. 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
  • Simply Wall St.

    Evoke Pharma (NASDAQ:EVOK) Has Debt But No Earnings; Should You Worry?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • GlobeNewswire

    Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

    SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief Business Officer, will participate virtually in the H.C. Wainwright 23rd Annual Global Investment Conference taking place from September 13 – 15, 2021. Event:H.C. Wainwright 23rd Annual Global Investment Confer

  • GlobeNewswire

    Evoke Pharma Reports Second Quarter 2021 Financial Results

    Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti® Extends cash runway into third quarter of 2022 SOLANA BEACH, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter that ended June 30, 2021 which includes recent corporate developments. “Throu